These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38824634)

  • 1. Health care resource utilization and costs associated with psychiatric comorbidities in adult patients with attention-deficit/hyperactivity disorder.
    Schein J; Cloutier M; Gauthier-Loiselle M; Bungay R; Chen K; Chan D; Childress A
    J Manag Care Spec Pharm; 2024 Jun; 30(6):588-598. PubMed ID: 38824634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare resource utilization and costs associated with psychiatric comorbidities in pediatric patients with attention-deficit/hyperactivity disorder: a claims-based case-cohort study.
    Schein J; Cloutier M; Gauthier-Loiselle M; Bungay R; Chen K; Chan D; Guerin A; Childress A
    Child Adolesc Psychiatry Ment Health; 2024 Jul; 18(1):80. PubMed ID: 38978130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
    Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
    J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of mental health comorbidities on health care utilization and expenditure in a large US managed care adult population with ADHD.
    Kawatkar AA; Knight TK; Moss RA; Sikirica V; Chu LH; Hodgkins P; Haim Erder M; Nichol MB
    Value Health; 2014 Sep; 17(6):661-8. PubMed ID: 25236989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Patterns Among Patients with Attention-Deficit/Hyperactivity Disorder and Comorbid Anxiety and/or Depression in the United States: A Retrospective Claims Analysis.
    Schein J; Childress A; Gagnon-Sanschagrin P; Maitland J; Bedard J; Cloutier M; Guérin A
    Adv Ther; 2023 May; 40(5):2265-2281. PubMed ID: 36913128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real world analysis of treatment change and response in adults with attention-deficit/hyperactivity disorder (ADHD) alone and with concomitant psychiatric comorbidities: results from an electronic health record database study is the United States.
    Liman C; Schein J; Wu A; Huang X; Thadani S; Childress A; Kollins SH; Bhattacharjee S
    BMC Psychiatry; 2024 Sep; 24(1):618. PubMed ID: 39285361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder.
    Secnik K; Swensen A; Lage MJ
    Pharmacoeconomics; 2005; 23(1):93-102. PubMed ID: 15693731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct medical costs of ADHD and its comorbid conditions on basis of a claims data analysis.
    Libutzki B; Ludwig S; May M; Jacobsen RH; Reif A; Hartman CA
    Eur Psychiatry; 2019 May; 58():38-44. PubMed ID: 30802682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burden of illness and health care resource utilization in adult psychiatric outpatients with attention-deficit/hyperactivity disorder in Europe.
    Karlsdotter K; Bushe C; Hakkaart L; Sobanski E; Kan CC; Lebrec J; Kraemer S; Dieteren NA; Deberdt W
    Curr Med Res Opin; 2016 Sep; 32(9):1547-56. PubMed ID: 27171913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.
    Wu EQ; Birnbaum HG; Zhang HF; Ivanova JI; Yang E; Mallet D
    J Manag Care Pharm; 2007 Sep; 13(7):561-9. PubMed ID: 17874862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors associated with newly diagnosed attention-deficit/hyperactivity disorder in adults: a retrospective case-control study.
    Schein J; Cloutier M; Gauthier-Loiselle M; Bungay R; Arpin E; Guerin A; Childress A
    BMC Psychiatry; 2023 Nov; 23(1):870. PubMed ID: 37996794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions.
    Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
    J Manag Care Spec Pharm; 2020 Aug; 26(8):996-1007. PubMed ID: 32552362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic burden of generalized myasthenia gravis (MG) in the United States and the impact of common comorbidities and acute MG-events.
    Zhdanava M; Pesa J; Boonmak P; Cai Q; Pilon D; Choudhry Z; Souayah N
    Curr Med Res Opin; 2024 Jul; 40(7):1145-1153. PubMed ID: 38745448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health care resource utilization and direct costs incurred over 24 months after initiating galcanezumab or standard-of-care preventive migraine treatments in the United States.
    Varnado OJ; Vu M; Buysman E; Kim G; Allenback G; Hoyt M; Trenz H; Cao F; Viktrup L
    J Manag Care Spec Pharm; 2024 Aug; 30(8):792-804. PubMed ID: 39088336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit hyperactivity disorder in quebec.
    Lachaine J; De G; Sikirica V; Van Stralen J; Hodgkins P; Yang H; Heroux J; Ben Amor L
    Can J Psychiatry; 2014 Nov; 59(11):597-608. PubMed ID: 25565476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical Expenditures Associated with Attention-Deficit/Hyperactivity Disorder Among Adults in the United States by Age, 2015-2019.
    Witrick B; Zhang D; Su D; Li Y; McCall WV; Hendricks B; Shi L
    J Gen Intern Med; 2023 Jul; 38(9):2082-2090. PubMed ID: 36781580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorder.
    Schein J; Cloutier M; Bungay R; Gauthier-Loiselle M; Childress A
    J Med Econ; 2024; 27(1):653-662. PubMed ID: 38602691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare utilization and costs of psychiatric and somatic comorbidities associated with newly diagnosed adult ADHD.
    Garcia-Argibay M; Pandya E; Ahnemark E; Werner-Kiechle T; Andersson LM; Larsson H; Du Rietz E
    Acta Psychiatr Scand; 2021 Jul; 144(1):50-59. PubMed ID: 33749845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
    Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
    J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.